Despite their demonstrated abilities to elicit anti-tumor effects, the efficacy of NPs carrying PD-1/PD-L1 ICIs can be limited by physiological obstacles that impair delivery to tumor tissues. This evidence concerns the gene CD274 and neoplasm.